While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
Stocks of Indian companies with exposure to Europe fell on Tuesday amid concerns about the impact on their sales in case the Russia-Ukraine crisis worsens and the US and its allies impose economic sanctions on Russia. While top conglomerates, including Reliance Industries, the Tata group, and Aditya Birla Group, said they did not have any significant exposure to Russia, executives of some of the oil and gas, pharmaceutical, and tea companies said they were monitoring the situation closely as they earned substantial income from the region. Russian President Vladimir Putin on Monday ordered troops into two breakaway regions of eastern Ukraine after announcing that Russia would recognise their independence.
Such businesses outperform non-family firms by 3% in first six months of CY20, says Credit Suisse report.
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
"Sputnik will probably offer vaccines after June 20. They will start the vaccine production from the month of August. They are importing the vaccines right now, and they will allot a section of their imported vaccines to the Delhi government," he said.
The announcement comes a day after the Subject Expert Committee (SEC) on COVID-19 of the CDSCO recommended granting emergency use authorisation (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions.
It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.
The recent recalls come amid increased FDA scrutiny of medicines produced in India.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.
The CoWIN portal will be made available in Hindi and 14 regional languages by next week, while 17 more laboratories will be added to the INSACOG network to monitor the variants of COVID-19, the health ministry said on Monday.
Indian auto and pharma industries import several critical components and raw materials from China.
The government was hoping to roll out the GST regime from April 2016.
'A good 30 per cent of people will still get infected after getting the Covishield vaccine.'
Apart from favipiravir and remdesivir, its key Covid-19 products, DRL has already launched nutraceutical products and hand sanitisers during the pandemic.
Top officers across various ministries participate in the meeting that started at 8 pm on Saturday. The meeting is currently underway. The country is currently witnessing a second and more severe wave of the pandemic.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
At 8 million a month, times two doses, it will take us 17 years to administer the vaccine to our 800 million adults. The rollout must speed up twenty times, asserts Naushad Forbes.
The drug that it would supply is called Olanzapine, used to treat schizophrenia and bipolar disorder.
Indian Council of Medical Research Director General Balram Bhargava said the purpose of the COVID vaccine drive would be to break the chain of viral transmission.
The US drug regulator raised the issue of significant deviations from the current good manufacturing practice (cGMP) in three of DRRD's plants in a letter issued in November 2015
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Nadella advised the start-up community to learn from the failures
Telangana chief minister K Chandrasekhar Rao on Wednesday announced the establishment of a massive industrial park dedicated to pharmaceutical manufacturing activities.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
DRL launched four new products in North America during the previous quarter.
NTPC, Sun Pharma Coal India and Asian Paints were among top losers on BSE Sensex
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
Indian pharma firms under European drug regulator's scanner.
As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
The institute's incubation cell claims the start up mortality rate in the incubators are lowest.
Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.
The S&P BSE Sensex ended the session at 25,342, up 3 points while the Nifty50 closed at 7,738 points.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances